News Featured April 7, 2026 Nemera and Therakind Announce Strategic Partnership to Advance DriDose® Dry Powder Intranasal Technology April 7, 2026 Read more → April 7, 2026 November 14, 2024 Therakind receives grant award from Innovate UK November 14, 2024 Read more → November 14, 2024 November 1, 2024 Therakind Sponsors Drug Delivery to Lung Forum 2024 November 1, 2024 Read more → November 1, 2024 October 14, 2024 Therakind is attending BIO Europe 2024 October 14, 2024 Read more → October 14, 2024 September 23, 2024 Therakind Presents a Poster at the 3rd Annual Inhaled & Nasal Biologics Forum 2024 September 23, 2024 Read more → September 23, 2024 May 30, 2024 Oresund Pharma acquires the international rights outside the US for Therakind’s oncology and autoimmune product, Jylamvo® May 30, 2024 Read more → May 30, 2024 May 27, 2024 US patent granted for Therakind’s DriDose® multi-dose delivery system May 27, 2024 Read more → May 27, 2024 May 22, 2024 Therakind is attending BIO 2024 May 22, 2024 Read more → May 22, 2024 March 25, 2024 Therakind completes Management Buy-Out March 25, 2024 Read more → March 25, 2024 November 30, 2023 Therakind Sponsors DDL 2023 November 30, 2023 Read more → November 30, 2023 October 31, 2023 Shorla Oncology Announces US Acquisition of Jylamvo, an Oncology and Autoimmune Drug from Therakind October 31, 2023 Read more → October 31, 2023 March 28, 2023 Therakind’s DriDose® Dry Powder Intranasal Device Delivers Vaccine March 28, 2023 Read more → March 28, 2023 May 12, 2022 Therakind enters exclusive distribution partnership with Oresund Pharma May 12, 2022 Read more → May 12, 2022 August 9, 2021 Therakind collaborates with Indosys to develop a novel dry powder nasal device August 9, 2021 Development of a new drug delivery platform Read more → August 9, 2021 December 2, 2020 Brazilian patent granted for Therakind novel dry powder nasal device DriDose® December 2, 2020 Brazil patent granted for Therakind novel dry powder nasal device DriDose® Read more → December 2, 2020 September 1, 2020 Therakind acquires IP to novel dry powder nasal device, DriDose® September 1, 2020 DriDose® to form basis of Therakind novel delivery platform Read more → September 1, 2020 September 1, 2020 Therakind acquires IP to novel dry powder nasal device, DriDose® September 1, 2020 DriDose® to form basis of Therakind novel delivery platform Read more → September 1, 2020 June 1, 2020 Therakind attends Digital BIO 2020 June 1, 2020 Therakind attends Digital BIO 2020 Read more → June 1, 2020 March 14, 2020 Therakind enters exclusive distribution partnership with BioJam Holding Group March 14, 2020 Launch of Jylamvo in Portugal Read more → March 14, 2020 January 9, 2020 Therakind enters exclusive distribution partnership with Pharmalink January 9, 2020 Jylamvo targets United Arab Emirates market Read more → January 9, 2020
